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1. Introduction 
Platelet activity has a very important role in the pathogenesis of atherosclerosis disease. In 
addition to being part of the coagulation system, they contribute to all phases of the 
atherosclerosis process (1) The “intervention” in the platelet activity has been played a 
central role in the treatment of coronary artery disease (CAD) (2). 
Aspirin is considered the foundation antiplatelet therapy for patients at risk of 
cardiovascular events. However, in the last few decades many different agents were 
introduced to have a more effective antiplatelet action and improve treatment outcomes in 
coronary syndromes. 
In this chapter you will find a systematic review of all the antiplatelet agents available: 
mechanism of action, pharmacokinetics, side effects, evidence of effectiveness and their use 
in clinical settings. A special emphasizes will point out agents that are in investigational 
stage and what are the future perspectives. 
1.1 Platelet mechanisms of action 
Platelets play a critical role in the normal coagulation system by “preventing” bleeding after 
blood vessels are damaged.  In addition they contribute to different phases of the atherosclerotic 
process (1). Rupture of a previously formed atherosclerotic plaque exposes collagen, smooth-
muscle cells and von Willebrand factor (vWF) all of which trigger platelet activation and 
massive aggregation (3). The result of this accumulation of platelets is thrombosis. Acute 
coronary syndrome (ACS) is a consequence of the occlusion of an atherosclerotic vessel by the 
thrombotic process.  As described before, collagen and vWF in addition to thromboxane A2 
(TXa2), thrombin and adenosine diphosphate (ADP) are the most powerful platelet activators 
(4).  When a platelet is activated a conformational change occurs in a receptor located in the 
platelet membrane called glycoprotein IIb/IIIa which promotes platelet aggregation (5).  
Antiplatelet agents that target critical steps of the thrombotic mechanism described above 
have been developed in the last three decades.  However, treatment with these agents can 
sometimes increase the risk of “undesirable” bleeding complications (6). 
2. The traditional anti-platelet agents 
Many anti-platelet agents have been tested and used as an effective treatment in arterial 
thrombosis. Acetyl salicylic acid, commonly known as aspirin was the first anti-platelet 
www.intechopen.com
  
Acute Coronary Syndromes 
 
2 
agent used and proven to be effective to reduce the incidence of myocardial infarction and 
stroke in many high risk vascular patients (2).The recurrence of vascular events in 
patients treated with aspirin alone ranges between 10 – 20% within five years of the initial 
event (2-7).  
Aspirin is effective by blocking the synthesis of TXa2, a powerful platelet activator.  
In the last decade, the thienopyridines such as clopidogrel have been used to improve 
outcomes in the treatment of ACS.  This anti-platelet agent irreversibly blocks the P2Y12 
receptor, precluding the platelet activation by ADP (2).  Its anti-platelet mechanism of action 
clearly differs from aspirin.  In the majority of cardiovascular patients the combination of 
clopidogrel and aspirin has additive beneficial effects when compared with clopidogrel or 
aspirin alone (8).  Clopidogrel also has some limitations, which have prompted the 
development of newer anti-platelet agents which interact at different sites of the coagulation 
cascade. 
The following figure reflects the site of action of the common antiplatelet agents (figure 1)  
3. The thromboxane A2 antagonist 
Dipyridamole (Persantine) acts as a thromboxane synthase inhibitor, therefore lowering the 
levels of TXA2 and thus stops the effects of TXA2 as a platelet activator (9). 
Also can causes systemic vasodilation when given at high doses over a short period of time. 
The latter, due to the inhibition of the cellular reuptake of adenosine into platelets, red blood 
cells and endothelial cells leading to increased extracellular concentrations of adenosine (9). 
It also inhibits the enzyme adenosine deaminase, which normally breaks down adenosine 
into inosine. This inhibition leads to further increased levels of extracellular adenosine, 
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Modified release dipyridamole is used in conjunction with aspirin (under the trade names 
Aggrenox in the USA or Asasantin Retard in the UK) in the secondary prevention of stroke 
and transient ischemic attack. This practice has been confirmed by the ESPRIT trial (9). A 
triple therapy of aspirin, clopidogrel and dipyridamole has been investigated, but this 
combination led to an increase in adverse bleeding events (10). 
Via the mechanisms mentioned above, when given as 3 to 5 min infusion it rapidly increases 
the local concentration of adenosine in the coronary circulation which causes vasodilation. 
Vasodilation occurs in healthy arteries, whereas stenosed arteries remain narrowed. This 
creates a "steal" phenomenon where the coronary blood supply will increase to the dilated 
healthy vessels compared to the stenosed arteries which can then be detected by clinical 
symptoms of chest pain, electrocardiogram and echocardiography when it causes ischemia. 
Flow heterogeneity (a necessary precursor to ischemia) can be detected with gamma cameras 
and SPECT using nuclear imaging agents such as Thallium-201 and Tc99m-Sestamibi (9). 
Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane 
induced platelet aggregation and vasoconstriction (11). As of 2010, it is being tested for the 
secondary prevention of acute thrombotic complications in the Phase III clinical trial. 
However, the recent publication of the finalized trial PERFORMS shown no clinical 
advantage in comparison with patients with aspirin monotherapy in preventing strokes (12). 
At the time of this publication its use in clinical practice is not approved in the USA. 
4. Other P2Y 12 antagonist 
Ticlopidine an anti-platelet drug in the thienopyridine family inhibits platelet aggregation 
by altering the function of platelet membranes by irreversibly blocking ADP receptors. This 
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prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding 
to fibrinogen (13).  It is used in patients in whom aspirin is not tolerated, or in whom dual 
anti-platelet therapy is desirable (in combination with Aspirin).  Because it has been 
reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and 
neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is 
felt to have a much lower hematologic risk (14). 
Prasugrel, a novel thienopyryridine was approved for clinical use in the USA by the Food 
and Drug Administration (FDA) in 2010.  Unlike clopidogrel, which undergoes a two-step, 
CYP450-dependent conversion to its active metabolite, prasugrel only requires single-step 
activation.  Prasugrel is a more potent platelet inhibitor with faster action and inhibition.  
Also, it has been estimated that due to its “easy metabolism” its genetic resistance is less 
likely (15). In other words, prasugrel has a significantly lower incidence of hypo-
responsiveness in comparison with clopidogrel (15). However, the risks of bleeding in these 
patients are greater than clopidogrel (16). 
Ticagrelor is the most novel class of anti-platelet drugs, the cyclopentytriazolopyrimides, 
which also inhibit the P2Y12 receptor as the thienopyryridines.  However, it has a simpler 
and faster metabolism (rapid onset of action) high potency and most importantly 
reversibility (17). The latter, makes this drug safer in regards of bleeding complications. 
Cangrelor, an ATP analog, is an investigational intravenous anti-platelet drug. This agent 
has biphasic elimination and possesses the advantages of high potency, very fast onset of 
action and very fast reversibility after the discontinuation (16).This gives a considerable 
advantage over other ADP antagonist in patients who might need immediate surgery. 
However, after initial treatment, patients who received intravenous infusion of Cangrelor 
often require continued treatment with one of the oral P2Y12 antagonists, something that 
one must take into consideration (16).  
5. Glycoproteins IIb/IIa antagonist 
Abciximab, more known as the ReoPro is an antibody against glycoprotein IIb/IIIa receptor.  It 
had a lot of popularity within interventional cardiologist 10 years ago.  It is barely used today.  
It was replaced by newer IV agents. Abciximab has a plasma half-life of about ten minutes, with 
a second phase half-life of about 30 minutes. However, its effects on platelet function can be 
seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein 
IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated (18). 
Tirobiban (Aggrastat) is a synthetic, non-peptide inhibitor acting at glycoprotein (GP) IIb/IIIa 
receptors.  It has a rapid onset and short duration of action after proper intravenous 
administration.  Platelet activity returns to normal 4 to 8 hours after the drug is withdrawn (19). 
Eptifibatide (Integrilin) is the newer anti-platelet drug which inhibits the glycoprotein IIb/IIIa 
inhibitor.  It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and 
reversibly binds to platelets.  Eptifibatide has a short half-life, 3 to 5 hours after the 
discontinuation platelet activity recovers to normal levels (20).The drug is the third inhibitor of 
GPIIb/IIIa that has found broad acceptance within interventional cardiologists nowadays. 
6. Proteasa-activated receptors antagonist 
Vorapaxar (formerly SCH 530348) is a thrombin receptor (PAR-1) antagonist based on the 
natural product himbacine.  It is an experimental pharmaceutical treatment for acute coronary 
syndrome as a very powerful platelet inhibitor (21).In January 2011, the clinical trial was 
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halted for patients with stroke and mild heart conditions due to safety reasons. It is unknown 
if it will continue.  
7. Direct thrombin inhibitors 
Bivalirudin (Angiomax) is a specific and reversible intravenous direct thrombin inhibitor.  
Clinical studies demonstrated consistent positive outcomes in patients with stable angina, 
unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-
segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized 
trials (22).  Coagulation times and platelet activity return to baseline approximately 1-6 hour 
following cessation of bivalirudin administration (23). 
8. Conclusions 
Antiplatelet therapy plays a crucial role in the treatment of coronary patients.  The continuous 
introduction of new agents is geared to improve results in patient ongoing percutaneous 
coronary interventions.  However, the side effects of theses should be monitored closely.  In 
the end, the ideal management of patients with acute coronary syndrome should be to be a 
collaborative effort between cardiologist and surgeons to assure the best outcomes possible. 
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